Clinically Relevant Resistance in Cancer Chemotherapy: Cancer Treatment and Research, cartea 112
Editat de Borje Andersson, David Murrayen Limba Engleză Hardback – 31 oct 2002
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 706.97 lei 6-8 săpt. | |
Springer Us – 23 oct 2012 | 706.97 lei 6-8 săpt. | |
Hardback (1) | 716.29 lei 6-8 săpt. | |
Springer Us – 31 oct 2002 | 716.29 lei 6-8 săpt. |
Din seria Cancer Treatment and Research
- 5% Preț: 1080.67 lei
- 5% Preț: 711.64 lei
- 5% Preț: 771.65 lei
- 5% Preț: 1016.90 lei
- 5% Preț: 1011.74 lei
- 5% Preț: 1020.65 lei
- 5% Preț: 898.85 lei
- 5% Preț: 704.49 lei
- 5% Preț: 901.54 lei
- 5% Preț: 472.91 lei
- 5% Preț: 651.84 lei
- 5% Preț: 491.35 lei
- 5% Preț: 706.62 lei
- 5% Preț: 362.94 lei
- 15% Preț: 685.93 lei
- 5% Preț: 2073.87 lei
- 5% Preț: 1385.39 lei
- 5% Preț: 1395.26 lei
- 5% Preț: 1084.27 lei
- 5% Preț: 1271.32 lei
- 5% Preț: 1080.88 lei
- 5% Preț: 1072.26 lei
- 5% Preț: 1074.24 lei
- 5% Preț: 1384.89 lei
- 5% Preț: 705.54 lei
- 5% Preț: 692.48 lei
- 5% Preț: 1386.09 lei
- 5% Preț: 1086.24 lei
- 5% Preț: 1075.86 lei
- 5% Preț: 1070.10 lei
- 5% Preț: 1077.27 lei
- 5% Preț: 1083.90 lei
Preț: 716.29 lei
Preț vechi: 753.98 lei
-5% Nou
Puncte Express: 1074
Preț estimativ în valută:
137.13€ • 142.54$ • 113.69£
137.13€ • 142.54$ • 113.69£
Carte tipărită la comandă
Livrare economică 05-19 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781402072000
ISBN-10: 1402072007
Pagini: 404
Ilustrații: XX, 380 p.
Dimensiuni: 155 x 235 x 21 mm
Greutate: 0.8 kg
Ediția:2002
Editura: Springer Us
Colecția Springer
Seria Cancer Treatment and Research
Locul publicării:New York, NY, United States
ISBN-10: 1402072007
Pagini: 404
Ilustrații: XX, 380 p.
Dimensiuni: 155 x 235 x 21 mm
Greutate: 0.8 kg
Ediția:2002
Editura: Springer Us
Colecția Springer
Seria Cancer Treatment and Research
Locul publicării:New York, NY, United States
Public țintă
ResearchCuprins
List of contributors. Preface. 1. Tumor physiology and resistance to chemotherapy: repopulation and drug penetration; A.J. Davis, I.F. Tannock. 2. The role of membrane transporters in cellular resistance to anticancer nucleoside drugs; M.L. Clarke, et al. 3. MDR and MRP gene families as cellular determinant factors for resistance to clinical anticancer agents; L. Deng, et al. 4. The glutathione system in alkylator resistance; D. Hamilton, et al. 5. The role of signal transduction pathways in drug and radiation resistance; S. Grant, et al. 6. Mechanisms of repair of interstrand crosslinks in DNA; R.J. Legerski, C. Richie. 7. DNA repair in resistance to bifunctional alkylating and platinating agents; D. Murray. 8. Leukemic cell insensitivity to cyclophosphamide and other oxazaphosphorines mediated by aldehyde dehydrogenase(s); N.E. Sládek. 9. Mechanisms of resistance against cyclophosphamide and ifosfamide: can they be overcome without sacrificing selectivity? S.M. Ludeman, M.P. Gamcsik. 10. Cellular mechanisms of cyclophosphamide resistance: model studies in human medulloblastoma cell lines; H.S. Friedman, et al. 11. Model studies of cyclophosphamide resistance in human myeloid leukemia; B.S. Andersson, D. Murray. 12. Mechanisms of drug resistance in AML; M. Andreeff, M. Konopleva. 13. Biochemical and molecular mechanisms of cisplatin resistance; Z.H. Siddik. 14. Modification of radiosensitivity following chemotherapy exposure: potential implications for combined-modality therapy; R.A. Britten. 15. Clinical pharmacology of melphalan and itsimplications for clinical resistance to anticancer agents; R.B. Jones. 16. Pharmacological considerations of primary alkylators; J.S. McCune, J.T. Slattery. 17. Genomic approaches to clinical drug resistance; S. Damaraju, et al.Index.